CapsoVision, Inc. CV
6.85 USD +0.15 (+2.24%)
At closeNov 4, 2026, 4:01 PM EST
6.85 0.00 0.00%
After hours · Nov 4, 4:01 PM ET
6.79 Day range 7.05
4.50 52-week range 15.37
- YTD
- -35.92%
- 1 year
- +49.24%
- Market cap
- 364.49M
- EPS (ttm)
- -0.45
- YTD return
- -35.92%
- 1-year return
- +49.24%
- Volume
- 135.98K
- Avg volume
- 167.58K
- Open
- 6.81
- Previous close
- 6.70
- Day's range
- 6.79 – 7.05
- 52-week range
- 4.50 – 15.37
2Y +3.37 (+96.29%)
Financials — quick view
CV Revenue — quarterly 3.64M
CV Net income — quarterly -7.48M
CV EPS — quarterly -0.15
News
CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026 
CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer Screening 
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 
CapsoVision to Present at the 20th Annual LD Micro Main Event 
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease 
Head to Head Survey: CapsoVision (NASDAQ:CV) vs. Brainsway (NASDAQ:BWAY) 
CapsoVision (NASDAQ:CV) and NeuroPace (NASDAQ:NPCE) Critical Contrast 
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress 
CapsoVision gets FDA clearance for AI Highlights 
CapsoVision Receives FDA Clearance For Its AI Highlights Reading Tool For The CapsoCam Plus System
Your note
Sign in to keep a note on CV — it syncs with the Stock Master app.